Diagnos Laboratorium Utama Stock Net Income
| DGNS Stock | IDR 210.00 6.00 2.78% |
Diagnos Laboratorium Utama fundamentals help investors to digest information that contributes to Diagnos Laboratorium's financial success or failures. It also enables traders to predict the movement of Diagnos Stock. The fundamental analysis module provides a way to measure Diagnos Laboratorium's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Diagnos Laboratorium stock.
Diagnos |
Diagnos Laboratorium Utama Company Net Income Analysis
Diagnos Laboratorium's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Diagnos Laboratorium Net Income | 64.3 B |
Most of Diagnos Laboratorium's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Diagnos Laboratorium Utama is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Diagnos Laboratorium Utama reported net income of 64.3 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Diagnostics & Research industry. The net income for all Indonesia stocks is significantly lower than that of the firm.
Diagnos Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Diagnos Laboratorium's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Diagnos Laboratorium could also be used in its relative valuation, which is a method of valuing Diagnos Laboratorium by comparing valuation metrics of similar companies.Diagnos Laboratorium is currently under evaluation in net income category among its peers.
Diagnos Fundamentals
| Return On Equity | 0.0603 | |||
| Return On Asset | 0.0297 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 967.86 B | |||
| Shares Outstanding | 1.25 B | |||
| Shares Owned By Insiders | 80.00 % | |||
| Price To Earning | 10.49 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 302.18 B | |||
| Gross Profit | 148.56 B | |||
| EBITDA | 19.21 B | |||
| Net Income | 64.3 B | |||
| Cash And Equivalents | 52.8 B | |||
| Cash Per Share | 42.24 X | |||
| Total Debt | 10.45 B | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 7.26 X | |||
| Book Value Per Share | 171.17 X | |||
| Cash Flow From Operations | 58.87 B | |||
| Earnings Per Share | 51.84 X | |||
| Number Of Employees | 568 | |||
| Beta | 0.89 | |||
| Market Capitalization | 302.5 B | |||
| Total Asset | 241.98 B | |||
| Z Score | 17.8 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 241.98 B |
About Diagnos Laboratorium Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Diagnos Laboratorium Utama's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Diagnos Laboratorium using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Diagnos Laboratorium Utama based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Diagnos Stock
Diagnos Laboratorium financial ratios help investors to determine whether Diagnos Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diagnos with respect to the benefits of owning Diagnos Laboratorium security.